Marksans Pharma will participate in the Ashwamedh - Elara India Dialogue 2026 on September 2. The company confirmed the schedule in a filing with stock exchanges on September 1, 2026.

Meeting details

The event is a group meet scheduled for September 2, 2026. It will be held physically at the Hyatt in Santacruz East, Mumbai.

Regulatory disclosure

The intimation was issued pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Harshavardhan Panigrahi, Company Secretary of Marksans Pharma Ltd., signed the disclosure.

The company stated that no unpublished price sensitive information will be shared during the meet. The schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

Marksans Pharma shareholders approved a final dividend of ₹0.90 per equity share and reappointed key board members at its 34th annual general meeting held on August 27, 2026.

The meeting, conducted via video conferencing, saw all resolutions pass with requisite majorities. Shareholders also adopted the audited standalone and consolidated financial statements for FY26.

Voting Participation

A total of 2,50,569 shareholders were on record as of the August 20, 2026 cut-off date. Voting occurred through remote e-voting from August 24 to August 26, 2026, and during the AGM itself.

Promoters voted in full on all resolutions. Institutional participation remained high at over 80%, while non-institutional public participation stood at approximately 21.6%.

Resolution Outcomes

All four resolutions were passed. The dividend declaration and adoption of accounts faced negligible opposition. However, the reappointment of Dr. Sunny Sharma saw notable dissent from institutional investors.

Key Resolutions Passed

• Adoption of Financials: Approved with 100% support on polled votes. Only 7,427 votes were cast against.
• Final Dividend: A ₹0.90 (90%) dividend per share of Re. 1 face value was approved. It received 99.81% support, with 559,059 votes against.
• Director Reappointment: Dr. Sunny Sharma was reappointed upon retirement by rotation. The resolution passed with 98.81% support.
• WTD Appointment: Mrs. Sandra Saldanha was reappointed as Whole-time Director for three years starting September 25, 2026. This special resolution passed with 99.61% support.

What the Numbers Show

Institutional investors demonstrated selective dissent during the voting process. While institutions voted unanimously for the financial statements and dividend, they cast 3,543,780 votes against the reappointment of Dr. Sunny Sharma. This represented 5.94% of the votes polled by the institutional category, contrasting sharply with the near-unanimous support from promoters and non-institutional public shareholders.